Chapter title |
MicroRNA Dysregulation to Identify Novel Therapeutic Targets
|
---|---|
Chapter number | 34 |
Book title |
Viruses, Genes, and Cancer
|
Published in |
Current topics in microbiology and immunology, January 2017
|
DOI | 10.1007/82_2017_34 |
Pubmed ID | |
Book ISBNs |
978-3-31-961803-6, 978-3-31-961804-3
|
Authors |
Carlo M. Croce |
Abstract |
This paper describes how we discovered the juxtaposition of the MYC gene to the human immunoglobulin loci and how that finding was extended to characterize molecularly the t(14;18) chromosome translocation of follicular lymphoma and to clone the BCL2 gene. BCL2 is also overexpressed in CLL, the most common human leukemia. We discovered that most of human CLLs have a deletion of two microRNAs residing in the same polycistronic RNA, miR-15a and miR-16-1, and that these two microRNAs are negative regulators of BCL2. Thus, loss of miR-15/16 leads to overexpression of BCL2 that can be targeted by the new drug, venetoclax, that was recently approved by the FDA for the treatment of aggressive CLLs. |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 7 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Master | 3 | 43% |
Student > Doctoral Student | 1 | 14% |
Other | 1 | 14% |
Student > Ph. D. Student | 1 | 14% |
Student > Bachelor | 1 | 14% |
Other | 0 | 0% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 4 | 57% |
Chemistry | 1 | 14% |
Unknown | 2 | 29% |